Vestibular neuritis is one of the most common causes of dizziness and vertigo, with an estimated incidence of 3.5–15.5 per 100,000 persons. It is presumed to result from either a viral or vascular insult to the vestibulocochlear nerve or inner ear structures, leading to symptoms of intense vertigo.
The initial vertigo can last for hours to days. While many individuals fully recover, others are left with varying degrees of inner ear damage. Some may also develop auditory symptoms such as hearing loss or tinnitus (ear ringing). In these cases, the condition is more appropriately described as labyrinthitis rather than vestibular neuritis.
Those with more significant vestibular dysfunction or hearing loss are more likely to experience ongoing dizziness, disorientation, and communication difficulties—factors that can negatively impact quality of life and increase the risk of falls. As such, treatment aimed at minimizing damage and promoting recovery is essential.
“While many patients recover fully, those with lasting vestibular dysfunction may face persistent dizziness, communication challenges, and an increased risk of falls.”
In the acute stage, treatment typically includes vestibular suppressant medications to reduce the intensity of vertigo. Most patients are also prescribed steroids with the goal of reducing inflammation and promoting recovery.
While this has long been considered standard care, what does the current literature say about medical management of this condition?
Vestibular Suppressant Medication
In the acute phase, vestibular neuritis or labyrinthitis is commonly treated with vestibular suppressants such as meclizine. Medications for nausea (e.g., Zofran, Phenergan) may also be used.
These medications are intended to manage acute symptoms only and do not promote recovery or healing. They should not be used long term, as prolonged use can impair the brain’s ability to compensate and adapt to vestibular dysfunction.
Steroids
The evidence on the effectiveness of steroids in treating vestibular neuritis and labyrinthitis is mixed. Some studies suggest improved recovery of vestibular function, but there is no consistent evidence showing improvement in patient-reported symptoms or quality of life compared to placebo.
There is also mixed evidence regarding the role of steroids in hearing recovery in cases of sudden hearing loss. Early treatment may offer more benefit than delayed intervention, but this remains an area of ongoing debate.
Overall, the high rate of spontaneous recovery in these conditions contributes to uncertainty around steroid efficacy. Despite limited evidence of benefit, steroids remain part of the standard of care due to their relatively low risk of side effects—particularly when initiated soon after symptom onset.
Antiviral Medication
There is currently no evidence to support the use of antiviral medications in the treatment of vestibular neuritis or labyrinthitis, despite the presumed viral origin of these conditions.
This is likely because the initial viral insult has already occurred by the time symptoms present, and the primary issue becomes inflammation and swelling of the affected nerve rather than active viral replication.
Other Treatments
Vestibular rehabilitation therapy (VRT) is widely recognized as an effective treatment for promoting recovery and compensation. This specialized therapy helps the brain adapt to altered input from the damaged inner ear, reducing symptoms of dizziness and imbalance.
Referral for vestibular rehabilitation is strongly recommended, particularly for patients with persistent or more severe dysfunction following vestibular neuritis or labyrinthitis.
References:
Awad, Z., Huins, C., & Pothier, D. D. (2012). Antivirals for idiopathic sudden sensorineural hearing loss. The Cochrane Database of Systematic Reviews, 2012(8), CD006987. https://doi.org/10.1002/14651858.CD006987.pub2
Bae, C. H., Na, H. G., & Choi, Y. S. (2021). Current diagnosis and treatment of vestibular neuritis: A narrative review. Journal of Yeungnam Medical Science, 39(2), 81–88. https://doi.org/10.12701/yujm.2021.01228
Baloh, R. W. (2003). Vestibular neuritis. New England Journal of Medicine, 348(11), 1027–1032. https://doi.org/10.1056/NEJMcp021154
Bogdanova, A., Dlugaiczyk, J., Heckmann, J. G., & Schwab, S. (2022). Corticosteroids in patients with vestibular neuritis: An updated meta-analysis. Acta Neurologica Scandinavica, 146(5), 429–439. https://doi.org/10.1111/ane.13676
Chandrasekhar, S. S., Tsai Do, B. S., Schwartz, S. R., Bontempo, L. J., Faucett, E. A., Finestone, S. A., Hollingsworth, D. B., Kelley, D. M., Kmucha, S. T., Moonis, G., Poling, G. L., Roberts, J. K., Stachler, R. J., Zeitler, D. M., Corrigan, M. D., Nnacheta, L. C., & Satterfield, L. (2019). Clinical practice guideline: Sudden hearing loss(Update). Otolaryngology–Head and Neck Surgery, 161(S1). https://doi.org/10.1177/0194599819859885
Dailymed—Meclizine hydrochloride tablet meclizine hydrochloride tablet, chewable. (n.d.). Retrieved April 21, 2026, from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9ddc39c-bc6b-42f1-8c5f-5aff2d79c4bd
Edlow, J. A., Carpenter, C., Akhter, M., Khoujah, D., Marcolini, E., Meurer, W. J., Morrill, D., Naples, J. G., Ohle, R., Omron, R., Sharif, S., Siket, M., Upadhye, S., e Silva, L. O. J., Sundberg, E., Tartt, K., Vanni, S., Newman‐Toker, D. E., & Bellolio, F. (2023). Guidelines for reasonable and appropriate care in the emergency department 3 (grace ‐3): Acute dizziness and vertigo in the emergency department. Academic Emergency Medicine, 30(5), 442–486. https://doi.org/10.1111/acem.14728
Fishman, J. M., Burgess, C., & Waddell, A. (2011). Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (Vestibular neuritis). The Cochrane Database of Systematic Reviews, 2011(5), CD008607. https://doi.org/10.1002/14651858.CD008607.pub2
Greco, A., Macri, G. F., Gallo, A., Fusconi, M., De Virgilio, A., Pagliuca, G., Marinelli, C., & de Vincentiis, M. (2014). Is vestibular neuritis an immune related vestibular neuropathy inducing vertigo? Journal of Immunology Research, 2014, 459048. https://doi.org/10.1155/2014/459048
Hunter, B. R., Wang, A. Z., Bucca, A. W., Musey, P. I., Strachan, C. C., Roumpf, S. K., Propst, S. L., Croft, A., Menard, L. M., & Kirschner, J. M. (2022). Efficacy of benzodiazepines or antihistamines for patients with acute vertigo. JAMA Neurology, 79(9), 846–855. https://doi.org/10.1001/jamaneurol.2022.1858
Leong, K.-J., Lau, T., Stewart, V., & Canetti, E. F. D. (2021). Systematic review and meta-analysis: Effectiveness of corticosteroids in treating adults with acute vestibular neuritis. Otolaryngology–Head and Neck Surgery: Official Journal of American Academy of Otolaryngology-Head and Neck Surgery, 165(2), 255–266. https://doi.org/10.1177/0194599820982910
Oliveira J E Silva, L., Khoujah, D., Naples, J. G., Edlow, J. A., Gerberi, D. J., Carpenter, C. R., & Bellolio, F. (2023). Corticosteroids for patients with vestibular neuritis: An evidence synthesis for guidelines for reasonable and appropriate care in the emergency department. Academic Emergency Medicine: Official Journal of the Society for Academic Emergency Medicine, 30(5), 531–540. https://doi.org/10.1111/acem.14583
Rogers, T. S., Noel, M. A., & Garcia, B. (2023). Dizziness: Evaluation and management. American Family Physician, 107(5), 514–523.
Saberi, A., Pourshafie, S. H., Kazemnejad-Leili, E., Nemati, S., Sutohian, S., & Sayad-Fathi, S. (2019). Ondansetron or promethazine: Which one is better for the treatment of acute peripheral vertigo? American Journal of Otolaryngology, 40(1), 10–15. https://doi.org/10.1016/j.amjoto.2018.09.010
Sjögren, J., Magnusson, M., Tjernström, F., & Karlberg, M. (2019). Steroids for acute vestibular neuronitis-the earlier the treatment, the better the outcome? Otology & Neurotology: Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 40(3), 372–374. https://doi.org/10.1097/MAO.0000000000002106
Spiegel, R., Rust, H., Baumann, T., Friedrich, H., Sutter, R., Göldlin, M., Rosin, C., Müri, R., Mantokoudis, G., Bingisser, R., Strupp, M., & Kalla, R. (2017). Treatment of dizziness: An interdisciplinary update. Swiss Medical Weekly, 147, w14566. https://doi.org/10.4414/smw.2017.14566
Strupp, M., Zingler, V. C., Arbusow, V., Niklas, D., Maag, K. P., Dieterich, M., Bense, S., Theil, D., Jahn, K., & Brandt, T. (2004). Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. New England Journal of Medicine, 351(4), 354–361. https://doi.org/10.1056/NEJMoa033280
Zhao, Z., Liu, X., Zong, Y., Shi, X., & Sun, Y. (2023). Cellular processes induced by hsv-1 infections in vestibular neuritis. Viruses, 16(1), 12. https://doi.org/10.3390/v16010012
Brady Workman, AuD, is an audiologist in the Balance Disorders program at Wake Forest Baptist Health Center. He has authored several articles relating to balance and vestibular disorders as a regular contributor and co-editor of the Dizziness Depot at Hearing Health & Technology Matters. Brady received his doctorate of audiology from East Tennessee State University in 2018 and is licensed by the North Carolina Board of Examiners for Speech Language Pathologists and Audiologists and is a fellow of the American Academy of Audiology.
